University of Ottawa
Talk Session: SESSION 3: PEPTIDES IN THE CLINIC
Date: Sunday, June 12, 2022
Talk Time: 02:35 pm - 02:50 pm
Talk Title: Nano-Spray Gold-Peptide Therapy for Heart Attack Treatment
Feb/2018 – Present
Postdoctoral Fellow, University of Ottawa Heart Institute, Ottawa, Canada. Translational Research, managed over CAD$500,000 in 5 projects, ten scientific peer-review publications, one patent submission, 15 students’ supervision, managed purchase and operation of state-of-the-art instrumentation valued in CAD+$2M.
Mar/2012 – Dec/2014
CEO, Chilean Weightlifting Federation, Santiago, Chile. Developed the Olympic Sport at the national level and internationally. CAD$500,000 yearly budget, in charge of 10 full-time and 50 part-time employees. Increased organized events and marketing impact by over 200%, increased participants by over 50% nationally and achieved the participation of female and male athletes in the Olympic Games London 2012 and Rio 2016.
Jan/2007 – Jan/2018
Science Advisor for the Latin-Americas, International Weightlifting Federation, Budapest, Hungary. Science advisor for drug abuse in sport and drug testing in Latin Americas. Budget managed of CAD$100,000 yearly, over 15 countries developed anti-doping policies and testing over 1,000 samples per year, including drug testing manager Olympic and Paralympic Games Rio-2016.
Mar/2008 – Jul/2017
Academic Lecturer, Pontifical Catholic University of Chile, Santiago, Chile. Lecturer of Chemistry undergraduate courses, General Chemistry I and II, Organic Chemistry, and Analytical Chemistry.
We report the development, as well as the in vitro and in vivo testing, of a sprayable nano-therapeutic that uses surface engineered custom designed multi-armed peptide grafted nanogold for on-the-spot coating of infarcted myocardial surface.
When applied to mouse hearts, 1 week after infarction, the spray-on treatment resulted in an increase in cardiac function, 2.4-fold, muscle contractility, and myocardial electrical conductivity. The applied nanogold remaining at the treatment site 28 days post application with no off-target organ infiltration. Further, infarct size in the mice that received treatment was found to be <10% of the total left ventricle area, while the number of blood vessels, pro-healing macrophages, and cardiomyocytes increased to levels comparable to that of a healthy animal.
Our cumulative data suggests that the therapeutic action of our spray-on nanotherapeutic is highly effective and in practice its application is simpler than other regenerative approaches for treating the infarcted heart.